Algernon Pharmaceuticals CEO Christopher Moreau shared news that the company has announced it is planning a 180 patient, 3-month, Phase 2b clinical study of Ifenprodil for chronic cough. The study is set to begin in Q3 of 2023 and follows positive feedback from the US FDA at its pre-Investigational new drug meeting.

Contact Details

Proactive Canada

Proactive Canada

+1 604-688-8158


Copyright (c) 2023 TheNewswire - All rights reserved.